GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics - Finance news and analysis from Global Banking & Finance Review
Finance

Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics

Published by Global Banking & Finance Review

Posted on October 13, 2026

1 min read

· Last updated: October 13, 2026

Add as preferred source on Google
Finance Banking Markets

Roche Agrees to $1.16 Billion Obesity Drug Licensing Deal with Rona Therapeutics

Major Licensing Agreement in the Obesity Drug Market

ZURICH, Oct 13 (Reuters) - Swiss drugmaker Roche entered a licensing agreement worth up to $1.16 billion with Rona Therapeutics for its investigational obesity drug candidate, the Chinese biotech firm said on Tuesday. 

Roche’s Strategic Move in the Obesity Drug Market

Roche has been racing to break into the obesity drug market dominated by Eli Lilly and ​Novo Nordisk.

Deal Structure and Financial Terms

• With the deal, Rona Therapeutics is set to receive an upfront payment of $100 million and is eligible to receive up to $1.06 billion in potential milestone payments, as well as tiered royalties on global net sales.

Details on the Investigational Drug Candidate

• The investigational RNAi candidate targets activin receptor-like kinase 7 (ALK7), a target for obesity and metabolic diseases.

Recent Progress in Roche’s Obesity and Diabetes Portfolio

• In September, Roche reported positive mid-stage data for its obesity and diabetes candidate enicepatide, which helped patients lose weight and lower blood sugar levels.

Reporting and Editorial Notes

(Reporting by Marleen KaesebierEditing by Linda Pasquini)

Key Takeaways

  • Roche’s deal with Rona covers an ALK7‑targeting RNAi obesity therapy, with $100 million upfront, up to $1.06 billion in milestones and tiered royalties.
  • The agreement complements Roche’s broader push into obesity, alongside late‑stage development of enicepatide—a dual GLP‑1/GIP agonist showing ~15.5 % weight loss and significant HbA1c reductions in mid‑stage trials.
  • RNAi targeting of ALK7 represents a novel mechanism in obesity treatment, adding diversity to Roche’s pipeline already including petrelintide and combination therapies.

Frequently Asked Questions

What is the value of Roche's licensing agreement with Rona Therapeutics?
The licensing agreement is worth up to $1.16 billion, including an upfront payment of $100 million and up to $1.06 billion in milestone payments.
What drug candidate is covered in the deal between Roche and Rona Therapeutics?
The agreement covers an investigational RNAi obesity drug candidate targeting activin receptor-like kinase 7 (ALK7).
What will Rona Therapeutics receive as part of the deal?
Rona Therapeutics will receive a $100 million upfront payment, potential milestone payments totaling up to $1.06 billion, and tiered royalties on global net sales.
What recent advancements has Roche reported in obesity and diabetes treatments?
In September, Roche reported positive mid-stage results for its obesity and diabetes candidate enicepatide, which aided weight loss and blood sugar reduction.

Tags

Related Articles

Image for BMW deliveries fall 6.3% in third quarter as China sales slump

BMW deliveries fall 6.3% in third quarter as China sales slump

Image for Germany's Merz: I will prioritise welfare reform over popularity

Germany's Merz: I will prioritise welfare reform over popularity

Image for Italy seeks EU nod to use fiscal leeway to help families, not just green transition

Italy seeks EU nod to use fiscal leeway to help families, not just green transition

Image for Daily Mirror publisher Reach hit by Google traffic slump

Daily Mirror publisher Reach hit by Google traffic slump

Image for UK pub group Marston's upbeat on annual profit as sports-led pivot pays off

UK pub group Marston's upbeat on annual profit as sports-led pivot pays off

Image for Analysis-'Brutal session' for chip stocks shows AI trade is turning

Analysis-'Brutal session' for chip stocks shows AI trade is turning

More from Finance

Explore more articles in the Finance category

Image for Debt Maturity Can Matter as Much as the Interest Rate
Debt Maturity Can Matter as Much as the Interest Rate
Image for Kingfisher names Sebastian Gundel as new CEO
Kingfisher names Sebastian Gundel as new CEO
Image for LVMH's China letdown points to prolonged luxury industry pain
LVMH's China letdown points to prolonged luxury industry pain
Image for UK grocery inflation accelerates over last month, says Worldpanel
UK grocery inflation accelerates over last month, says Worldpanel
Image for Stellantis Q3 shipments fall 1%, weighed down by North America production halt
Stellantis Q3 shipments fall 1%, weighed down by North America production halt
Image for BP sees refining margin triple, debt target reached, but flags more impairments
BP sees refining margin triple, debt target reached, but flags more impairments
Image for UK recruiter Michael Page returns to profit growth after four-year slump
UK recruiter Michael Page returns to profit growth after four-year slump
Image for Premier Inn owner Whitbread backs turnaround plan, urges vote against Corvex seat
Premier Inn owner Whitbread backs turnaround plan, urges vote against Corvex seat
Image for UK's Bellway flags margin pressures in 2027 amid affordability and cost pressures
UK's Bellway flags margin pressures in 2027 amid affordability and cost pressures
Image for Finnair raises full-year guidance on strong demand 
Finnair raises full-year guidance on strong demand 
Image for Cyberattack affected 80 stores of French supermarket chain Co-Operative U
Cyberattack affected 80 stores of French supermarket chain Co-Operative U
Image for German September inflation confirmed at 3.3%
German September inflation confirmed at 3.3%
View All Finance Posts